177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer
- Author(s)
- Parihar, AS; Hofman, MS; Iravani, A;
- Details
- Publication Year 2023-02,Volume 306,Issue #2,Page e220859
- Journal Title
- Radiology
- Publication Type
- Review
- Abstract
- A 76-year-old man with metastatic castration-resistant prostate carcinoma progressing with antiandrogen and taxane therapy was treated with lutetium 177 prostate-specific membrane antigen (PSMA)-617 and showed marked biochemical and imaging response, with improvement in clinical status and osseous pain. A summary of nuclear medicine theranostics with emphasis on PSMA targeting agents is presented.
- Publisher
- Radiological Society of North America
- Keywords
- Aged; Humans; Male; Prostate/pathology; Prostate-Specific Antigen; *Prostatic Neoplasms, Castration-Resistant/chemically induced/drug; therapy/pathology; Treatment Outcome
- Department(s)
- Cancer Imaging
- PubMed ID
- 36125377
- Publisher's Version
- https://doi.org/10.1148/radiol.220859
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-13 07:55:10
Last Modified: 2023-06-13 07:56:08